New radioactive drug enters human testing for Hard-to-Treat tumors
NCT ID NCT07165132
Summary
This is the first human study of an experimental radioactive drug called RYZ401 for people with advanced neuroendocrine tumors and other solid tumors that have a specific marker. The main goals are to find the safest and most effective dose, check for side effects, and see if the treatment shows early signs of working. The study will enroll about 104 adults whose tumors have spread and who have not had certain prior radiation treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.